The drug decreases the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. Nilesh Gupta, MD, Lupin, ...
Lupin has received approval from Health Canada for pegfilgrastim, a biosimilar to Amgen's Neulasta. This product will be marketed under the brand name Armlupeg and manufactured at Lupin’s Biotech ...
ZURICH (Reuters) - The U.S. Food and Drug Administration has accepted Novartis unit Sandoz's submission for approval of a biosimilar version of U.S.-based Amgen's Neulasta drug that fights infections ...
Pegfilgrastim helps prevent myelosuppression in women undergoing chemotherapy for breast cancer but can also cause severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results